Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma

Hematology/Oncology Clinics of North America

Volumn 28, Issue 3, 2014, Pages 523-536

  Chen, Guo ^a   Davies, Michael A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Combination therapy; Drug resistance; MAPK; Melanoma; PI3K AKT; Tumor heterogeneity

Indexed keywords

ADENYLATE CYCLASE; B RAF KINASE INHIBITOR; COBIMETINIB; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN BAD; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SOMATOMEDIN C RECEPTOR; TRAMETINIB; UNINDEXED DRUG; VEMURAFENIB; B RAF KINASE; PROTEIN KINASE INHIBITOR;

ALTERNATIVE RNA SPLICING; ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; CELL CYCLE PROGRESSION; DRUG MECHANISM; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMAN; MELANOMA; MELANOMA CELL; MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; BIOLOGICAL MODEL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MUTATION; PROCEDURES; SKIN NEOPLASMS;

DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; MODELS, GENETIC; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84901464287     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.03.001     Document Type: Review

References (63)

1. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
2. Wan P.T., Garnett M.J., Roe S.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
3. Karasarides M., Chiloeches A., Hayward R., et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298.
4. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006, 95:581-586.
5. Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. NEngl J Med 2010, 363:809-819.
6. Falchook G.S., Long G.V., Kurzrock R., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
7. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEngl J Med 2011, 364:2507-2516.
8. Hauschild A., Grob J.J., Demidov L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
9. Bollag G., Hirth P., Tsai J., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
10. Trunzer K., Pavlick A.C., Schuchter L., et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. JClin Oncol 2013, 31:1767-1774.
11. Shi H., Hugo W., Kong X., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014, 4:80-93.
12. Dumaz N., Hayward R., Martin J., et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006, 66:9483-9491.
13. Van Allen E.M., Wagle N., Sucker A., et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014, 4:94-109.
14. Nazarian R., Shi H., Wang Q., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
15. Das Thakur M., Salangsang F., Landman A.S., et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013, 494:251-255.
16. Shi H., Moriceau G., Kong X., et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012, 3:724.
17. Poulikakos P.I., Persaud Y., Janakiraman M., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
18. Nikolaev S.I., Rimoldi D., Iseli C., et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 2012, 44:133-139.
19. Shi H., Moriceau G., Kong X., et al. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAFi. Cancer Discov 2012, 2:414-424.
20. Wagle N., Emery C., Berger M.F., et al. Dissecting therapeutic resistance to RAFinhibition in melanoma by tumor genomic profiling. JClin Oncol 2011, 29:3085-3096.
21. Maertens O., Johnson B., Hollstein P., et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 2013, 3:338-349.
22. Whittaker S.R., Theurillat J.P., Van Allen E., et al. Agenome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013, 3:350-362.
23. Kwong L.N., Davies M.A. Targeted therapy for melanoma: rational combinatorial approaches. Oncogene 2014, 33:1-9.
24. Fruman D.A., Meyers R.E., Cantley L.C. Phosphoinositide kinases. Annu Rev Biochem 1998, 67:481-507.
25. Davies M.A. The role of the PI3K-AKT pathway in melanoma. Cancer J 2012, 18:142-147.
26. Nathanson K.L., Martin A.M., Wubbenhorst B., et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 2013, 19:4868-4878.
27. Paraiso K.H., Xiang Y., Rebecca V.W., et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011, 71:2750-2760.
28. Deng W., Gopal Y.N., Scott A., et al. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 2012, 25:248-258.
29. Xing F., Persaud Y., Pratilas C.A., et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 2012, 31:446-457.
30. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
31. Villanueva J., Vultur A., Lee J.T., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683-695.
32. Lito P., Pratilas C.A., Joseph E.W., et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012, 22:668-682.
33. Straussman R., Morikawa T., Shee K., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
34. Abel E.V., Basile K.J., Kugel C.H., et al. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. JClin Invest 2013, 123:2155-2168.
35. Girotti M.R., Pedersen M., Sanchez-Laorden B., et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 2013, 3:158-167.
36. Hunter T., Pines J. Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell 1994, 79:573-582.
37. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. NEngl J Med 2005, 353:2135-2147.
38. Smalley K.S., Lioni M., Dalla Palma M., et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008, 7:2876-2883.
39. Garraway L.A., Widlund H.R., Rubin M.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
40. Haq R., Shoag J., Andreu-Perez P., et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 2013, 23:302-315.
41. Johannessen C.M., Johnson L.A., Piccioni F., et al. Amelanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013, 504:138-142.
42. Wagle N., Van Allen E.M., Treacy D.J., et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK Inhibition. Cancer Discov 2014, 4:61-68.
43. Burrell R.A., McGranahan N., Bartek J., et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501:338-345.
44. Wilmott J.S., Tembe V., Howle J.R., et al. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 2012, 11:2704-2708.
45. Paraiso K.H., Fedorenko I.V., Cantini L.P., et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010, 102:1724-1730.
46. Flaherty K.T., Robert C., Hersey P., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. NEngl J Med 2012, 367:107-114.
47. Flaherty K.T., Infante J.R., Daud A., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. NEngl J Med 2012, 367:1694-1703.
48. Sosman JA, Daud A, Weber JS, etal. BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM) [abstract 9005]. In: Abstracts of 2013 American Society of Clinical Oncology Annual Meeting. Chicago: J Clin Oncol 2013;31:9005.
49. Menzies A.M., Long G.V. New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol 2013, 5:278-285.
50. Emery C.M., Vijayendran K.G., Zipser M.C., et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009, 106:20411-20416.
51. Villanueva J., Infante J.R., Krepler C., et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep 2013, 4:1090-1099.
52. Morris E.J., Jha S., Restaino C.R., et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013, 3:742-750.
53. Jameson K.L., Mazur P.K., Zehnder A.M., et al. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med 2013, 19:626-630.
54. Carlino M.S., Todd J.R., Gowrishankar K., et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol 2014, [Epub ahead of print].
55. Shi H., Hong A., Kong X., et al. Anovel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov 2014, 4:69-79.
56. Finn RS, Crown JP, Lang I, etal. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC) [Abstract nr S1-6]. In: Abstracts of the 35th Annual Cancer Therapy & Research Center at UT Health Science Center San Antonio -American Association for Cancer Research Breast Cancer Symposium. San Antonio: Ann Oncol 2012;23:ii43-5.
57. Young R.J., Waldeck K., Martin C., et al. Loss of CDKN2A Expression is a frequent event in primary invasive melanoma and correlates with Sensitivity to the CDK4/6inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res 2014, [Epub ahead of print]. 10.1111/pcmr.12228.
58. Yokoyama S., Feige E., Poling L.L., et al. Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 2008, 21:457-463.
59. Boni A., Cogdill A.P., Dang P., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010, 70:5213-5219.
60. Wilmott J.S., Long G.V., Howle J.R., et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012, 18:1386-1394.
61. Frederick D.T., Piris A., Cogdill A.P., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013, 19:1225-1231.
62. Hong D.S., Vence L., Falchook G., et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res 2012, 18:2326-2335.
63. Liu C., Peng W., Xu C., et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013, 19:393-403.